Zhenhua Ren

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

Cancer research

Science translational medicine

The University of Texas Southwestern Medical Center

Chinese Academy of Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Texas Southwestern Medical Center

United States

Postdoctoral Researcher :: Pathlogy

Education History

Chinese Academy of Sciences

China

PHD

China Agricultural University

China

BSC

Publications

Zhenhua Ren, Xuhao Zhang, Yang-Xin Fu
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Zhenhua Ren, Xuhao Zhang, Yang-Xin Fu
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
Zhenhua Ren, Xuhao Zhang, Yang-Xin Fu
Facts and hopes on chimeric cytokine agents for cancer immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Anli Zhang, Zhenhua Ren, Kuo-Fu Tseng, Xiaojuan Liu, Huiyu Li, Changzheng Lu, Yueqi Cai, John D Minna, Yang-Xin Fu
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Science translational medicine 13 (605) (2021)
Yong Wang, Maowu Luo, Yan Chen, Bo Zhang, Zhenhua Ren, Lei Bao, Jennifer E Wang, Yang-Xin Fu, Yingfei Wang
ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. Cancer research 81 (1) (2020)
Chuanhui Han, Zhida Liu, Yunjia Zhang, Aijun Shen, Chunbo Dong, Anli Zhang, Casey Timmerman, Zhenhua Ren, Changzheng Lu, Xuezhi Cao, Chun-Li Zhang, Jian Qiao, Yang-Xin Fu
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature immunology 21 (5) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 11 (1) (2020)
Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric J Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology 4 (38) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 10 (1) (2019)

Zhenhua Ren.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zhenhua Ren